Taysha Gene Therapies Inc. (NASDAQ:TSHA) is highlighted as a small-cap stock pick with significant potential by billionaire Steve Cohen. Raymond James has initiated coverage on Taysha with a Strong Buy rating and a $13 price target, citing positive Phase 1/2 REVEAL trial results for Rett syndrome. Taysha focuses on AAV-based gene therapies for rare disorders affecting the central nervous system, with recent breakthroughs in therapy designation and FDA alignment. Patient enrollment for REVEAL Part B is ongoing, aiming for final dosing by mid-2026 and potential commercialization in 2027.

Read more at Yahoo Finance: Raymond James Initiates Strong Buy on Taysha (TSHA) Amid Rett Syndrome Trial Momentum